<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4099723</article-id><article-id pub-id-type="publisher-id">cc2603</article-id><article-id pub-id-type="doi">10.1186/cc2603</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven<sup>&#x000ae;</sup>) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Thabut</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>de Franchis</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Bendtsen</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>D'Amico</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Albillos</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Abraldes</surname><given-names>JG</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Sofelt</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Bosch</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A9"><collab>the European Study Group on rFVIIa in UGI hemorrhage</collab></contrib></contrib-group><aff id="I1"><label>1</label>Hospital Pitie-Salpetriere, Paris, France</aff><aff id="I2"><label>2</label>University of Milan, Italy</aff><aff id="I3"><label>3</label>Hvidovre Hospital, Copenhagen, Denmark</aff><aff id="I4"><label>4</label>Hospital Cervello, Palermo, Italy</aff><aff id="I5"><label>5</label>Hospital Ramon y Cajal, Madrid, Spain</aff><aff id="I6"><label>6</label>Hospital Clinic, Barcelona, Spain</aff><aff id="I7"><label>7</label>Novo Nordisk A/S, Copenhagen, Denmark</aff><pub-date pub-type="ppub"><year>2004</year></pub-date><pub-date pub-type="epub"><day>15</day><month>3</month><year>2004</year></pub-date><volume>8</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">24th International Symposium on Intensive Care and Emergency Medicine</named-content><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/supplements/notes/cc-8-s1-info.pdf">http://ccforum.com/supplements/notes/cc-8-s1-info.pdf</ext-link></supplement><fpage>P136</fpage><lpage>P136</lpage><conference><conf-date>30 March - 2 April 2004</conf-date><conf-name>24th International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Upper gastrointestinal bleeding (UGIB) is a severe and frequent complication of cirrhosis. Preliminary results show that rFVIIa may reduce bleeding in cirrhotic patients. This trial aimed to determine the efficacy and safety of rFVIIa in cirrhotic patients with variceal and nonvariceal UGIB.</p></sec><sec sec-type="methods"><title>Methods</title><p>Two hundred and forty-five cirrhotic patients (Child&#x02013;Pugh &#x0003c; 13; Child&#x02013;Pugh A = 20%, B = 52%, C = 28%) with UGIB (variceal = 66%, nonvariceal = 34%) were equally randomized to receive eight doses of 100 &#x003bc;g/kg rFVIIa or placebo in addition to pharmacologic and endoscopic treatment. The primary composite endpoint was the failure to control UGIB within 24 hours postdosing, or failure to prevent rebleeding between 24 hours and day 5, or death within 5 days.</p></sec><sec sec-type="results"><title>Results</title><p>Baseline characteristics were similar between the two groups. Results of primary and exploratory analyses are presented in Table <xref ref-type="table" rid="T1">1</xref>. In the subgroup of Child&#x02013;Pugh B and C variceal bleeders, significantly fewer patients in the rFVIIa-treated group failed on the primary composite endpoint (<italic>P </italic>= 0.03) and the 24 hour-bleeding control endpoint (<italic>P </italic>= 0.01) compared with placebo. rFVIIa did not improve the efficacy of standard treatment in Child&#x02013;Pugh A cirrhotic patients, and no significant effect was found when analysing all applicable patients. Incidences of adverse events including thromboembolic events were similar, and there were no significant differences in 5-day or 42-day mortality.</p><table-wrap id="T1" position="float"><label>Table 1</label><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Placebo</th><th align="center">rFVIIa</th><th align="center"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Failure on composite endpoint</td><td/><td/><td/></tr><tr><td align="left">All patients</td><td align="center">19/123</td><td align="center">16/122</td><td align="center">0.72</td></tr><tr><td align="left">&#x02003;Variceal bleeders</td><td align="center">16/82</td><td align="center">8/79</td><td align="center">0.12</td></tr><tr><td align="left">&#x02003;Variceal bleeders Child B&#x02013;C</td><td align="center">15/65</td><td align="center">5/63</td><td align="center">0.03</td></tr><tr><td align="left">Failure to control acute bleeding (within 24 hours)</td><td/><td/><td/></tr><tr><td align="left">&#x02003;Variceal bleeders</td><td align="center">8/82</td><td align="center">2/79</td><td align="center">0.10</td></tr><tr><td align="left">&#x02003;Variceal bleeders Child B&#x02013;C</td><td align="center">7/65</td><td align="center">3/63</td><td align="center">0.01</td></tr><tr><td align="left">Failure to prevent rebleeding (24 hours-day 5)</td><td/><td/><td/></tr><tr><td align="left">&#x02003;Variceal bleeders</td><td align="center">9/82</td><td align="center">5/79</td><td align="center">0.40</td></tr><tr><td align="left">&#x02003;Variceal bleeders Child B&#x02013;C</td><td align="center">8/65</td><td align="center">3/63</td><td align="center">0.13</td></tr><tr><td align="left">Failure to control acute bleeding or failure to prevent rebleeding within 5 days</td><td/><td/><td/></tr><tr><td align="left">&#x02003;Variceal bleeders</td><td align="center">13/82</td><td align="center">6/79</td><td align="center">0.14</td></tr><tr><td align="left">&#x02003;Variceal bleeders Child B&#x02013;C</td><td align="center">12/65</td><td align="center">3/63</td><td align="center">0.03</td></tr></tbody></table><table-wrap-foot><p>Values are shown as failures/number of patients.</p></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Exploratory analyses in Child&#x02013;Pugh B and C cirrhotic patients indicated that administration of rFVIIa was safe and significantly reduced the proportion of patients who failed to control variceal bleeding. Further studies are needed to verify these findings.</p></sec></body></article>